Recent study suggested that Tau acetylation was a common factor in both traumatic brain injury (TBI) and AD, and may hold promise as a therapeutic target and potential blood biomarker of tauopathies (Shin et al., 2021). The gene discussed is MAPT; the disease is Alzheimer disease.